Free shipping on all orders over $ 500

Enasidenib

Cat. No. M4945

All AbMole products are for research use only, cannot be used for human consumption.

Enasidenib Structure
Synonym:

AG-221

Size Price Availability Quantity
10mM*1mL in DMSO USD 55 In stock
1mg USD 30 In stock
5mg USD 50 In stock
10mg USD 70 In stock
25mg USD 120 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Enasidenib is a potent and selective IDH2 (Isocitrate dehydrogenase 2) inhibitor with potential anticancer activity, with IC50s of 100 and 400 nM against IDH2R140Q and IDH2R172K, respectively. The inhibition of mutant IDH2 and its neoactivity is therefore a potential therapeutic treatment for cancer.

Enasidenib (AG-221) reverses the effects of mutant IDH2 on DNA methylation in mutant stem/progenitor cells. Enasidenib (AG-221) therapy induces differentiation of leukemic cells, with an increase in the CD11b+ population and a decrease in the c-Kit+ population in the peripheral blood at 2wks.

Chemical Information
Molecular Weight 473.37
Formula C19H17F6N7O
CAS Number 1446502-11-9
Solubility (25°C) DMSO 40 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Maria Paola Martelli, et al. Enasidenib and ivosidenib in AML

[2] No authors listed. Enasidenib

[3] No authors listed. Enasidenib

[4] Eytan M Stein, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Related Isocitrate Dehydrogenase (IDH) Products
AGI-5198

AGI-5198 (IDH-C35) is the first highly potent and selective inhibitor of IDH1 R132H and R132C mutants in vitro with IC50 values of 0.07 μM and 0.16 μM, respectively.

AGI-6780

AGI-6780 is a potent and selective inhibitor of IDH2 R140Q mutant with IC50 of 23 nM.

BAY-1436032

BAY1436032 is a novel pan-mutant IDH1 inhibitor, it specifically inhibits R-2HG production and colony growth, and induces myeloid differentiation of AML cells.

GSK864

GSK864 is a cell penetrant, potent and selective allosteric inhibitor of isocitrate dehydrogenase 1 (IDH1) that potently inhibits intracellular 2-hydroxyglutarate (2-HG) production in HT-1080 cells.

Ivosidenib

Ivosidenib is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: Enasidenib, AG-221 supplier, Isocitrate Dehydrogenase (IDH), inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.